EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system

Daniel J Herr iD, David A Elliott, Gillian Duchesne, Kristian D Stensland iD, Megan E V Caram iD, Christina Chapman iD, Jennifer A Burns, Brent K Hollenbeck, Jordan B Sparks iD, Chris Shin, Alexander Zaslavsky, Alexander Tsodikov und 1 weitere

Cancer · 15.10.2023 · 129 (20) · 3326-3333

DOI: 10.1002/cncr.34916 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 30.06.2023. Verfasst von Daniel J Herr und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Accurate information regarding real‐world outcomes after contemporary radiation therapy for localized prostate cancer is important for shared decision‐making. Clinically relevant end points at 10 years among men treated within a national health care delivery system were examined.

Methods

National administrative, cancer registry, and electronic health record data were used for patients undergoing definitive radiation therapy with or without concurrent androgen deprivation therapy within the Veterans Health Administration from 2005 to 2015. National Death Index data were used through 2019 for overall and prostate cancer–specific survival and identified date of incident metastatic prostate cancer using a validated natural language processing algorithm. Metastasis‐free, prostate cancer–specific, and overall survival using Kaplan–Meier methods were estimated.

Results

Among 41,735 men treated with definitive radiation therapy, the median age at diagnosis was 65 years and median follow‐up was 8.7 years. Most had intermediate (42%) and high‐risk (33%) disease, with 40% receiving androgen deprivation therapy as part of initial therapy. Unadjusted 10‐year metastasis‐free survival was 96%, 92%, and 80% for low‐, intermediate‐, and high‐risk disease. Similarly, unadjusted 10‐year prostate cancer–specific survival was 98%, 97%, and 90% for low‐, intermediate‐, and high‐risk disease. The unadjusted overall survival was lower across increasing disease risk categories at 77%, 71%, and 62% for low‐, intermediate‐, and high‐risk disease ( p < .001).

Conclusions

These data provide population‐based 10‐year benchmarks for clinically relevant end points, including metastasis‐free survival, among patients with localized prostate cancer undergoing radiation therapy using contemporary techniques. The survival rates for high‐risk disease in particular suggest that outcomes have recently improved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMaleHumansAndrogen AntagonistsAndrogensDisease-Free SurvivalProstate-Specific AntigenDelivery of Health CareTreatment Outcome

Stichwörter der Autor:innen

neoplasm metastasispopulationprostatic neoplasmsradiotherapysurvival

Substanzen

Androgen AntagonistsAndrogensProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
  • Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
  • HSR&D Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
  • Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

ORCID-Profile: Daniel J Herr, Kristian D Stensland, Megan E V Caram, Christina Chapman, Jordan B Sparks, Ted A Skolarus

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Herr, D. J., Elliott, D. A., Duchesne, G., Stensland, K. D., Caram, M. E. V., Chapman, C., Burns, J. A., Hollenbeck, B. K., Sparks, J. B., Shin, C., Zaslavsky, A., Tsodikov, A., & Skolarus, T. A. (2023). Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system. Cancer, 129(20), 3326-3333. https://doi.org/10.1002/cncr.34916

Vancouver

Herr DJ, Elliott DA, Duchesne G, Stensland KD, Caram MEV, Chapman C, et al. Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system. Cancer. 2023;129(20):3326-3333. doi:10.1002/cncr.34916

BibTeX
@article{Herr2023,
  author = {Herr, Daniel J and Elliott, David A and Duchesne, Gillian and Stensland, Kristian D and Caram, Megan E V and Chapman, Christina and Burns, Jennifer A and Hollenbeck, Brent K and Sparks, Jordan B and Shin, Chris and Zaslavsky, Alexander and Tsodikov, Alexander and Skolarus, Ted A},
  title = {Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system},
  journal = {Cancer},
  year = {2023},
  volume = {129},
  number = {20},
  pages = {3326--3333},
  doi = {10.1002/cncr.34916}
}
Kostenlos starten →